Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Metastasis-Directed Therapy in Prostate Cancer. Why, When, and How?

Phillips RM, Deek MP, Deweese TL, Tran PT.

Oncology (Williston Park). 2019 Oct 28;33(10). pii: 686509.

2.

Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.

Battaglia A, De Meerleer G, Tosco L, Moris L, Van den Broeck T, Devos G, Everaerts W, Joniau S.

Eur Urol Oncol. 2019 Mar;2(2):174-188. doi: 10.1016/j.euo.2018.09.005. Epub 2018 Oct 9. Review.

PMID:
31017094
3.

Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: From chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases.

Saluja R, Cheung P, Zukotynski K, Emmenegger U.

Urol Oncol. 2016 May;34(5):225-32. doi: 10.1016/j.urolonc.2016.02.016. Epub 2016 Mar 19. Review.

PMID:
27008982
4.

Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.

Siva S, Bressel M, Murphy DG, Shaw M, Chander S, Violet J, Tai KH, Udovicich C, Lim A, Selbie L, Hofman MS, Kron T, Moon D, Goad J, Lawrentschuk N, Foroudi F.

Eur Urol. 2018 Oct;74(4):455-462. doi: 10.1016/j.eururo.2018.06.004. Epub 2018 Jun 29.

PMID:
30227924
5.

Cytoreductive treatment strategies for de novo metastatic prostate cancer.

Connor MJ, Shah TT, Horan G, Bevan CL, Winkler M, Ahmed HU.

Nat Rev Clin Oncol. 2019 Nov 11. doi: 10.1038/s41571-019-0284-3. [Epub ahead of print] Review.

PMID:
31712648
6.

Stereotactic ablative body radiotherapy in patients with prostate cancer.

Loblaw A, Liu S, Cheung P.

Transl Androl Urol. 2018 Jun;7(3):330-340. doi: 10.21037/tau.2018.01.18. Review.

7.

Stereotactic ablative body radiotherapy (SAbR) for oligometastatic cancer.

Desai NB, Laine AM, Timmerman RD.

Br J Radiol. 2017 Feb;90(1070):20160500. doi: 10.1259/bjr.20160500. Epub 2016 Dec 23. Review.

8.

Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.

Kroeze SGC, Henkenberens C, Schmidt-Hegemann NS, Vogel MME, Kirste S, Becker J, Burger IA, Derlin T, Bartenstein P, Eiber M, Mix M, la Fougère C, Christiansen H, Belka C, Combs SE, Grosu AL, Müller AC, Guckenberger M.

Eur Urol Focus. 2019 Sep 5. pii: S2405-4569(19)30270-6. doi: 10.1016/j.euf.2019.08.012. [Epub ahead of print]

PMID:
31495759
9.

Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.

Palma DA, Olson R, Harrow S, Correa RJM, Schneiders F, Haasbeek CJA, Rodrigues GB, Lock M, Yaremko BP, Bauman GS, Ahmad B, Schellenberg D, Liu M, Gaede S, Laba J, Mulroy L, Senthi S, Louie AV, Swaminath A, Chalmers A, Warner A, Slotman BJ, de Gruijl TD, Allan A, Senan S.

BMC Cancer. 2019 Aug 19;19(1):816. doi: 10.1186/s12885-019-5977-6.

10.

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).

Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES, Deville C, Greco S, Denmeade S, Paller C, Song DY, Diehn M, Wang H, Carducci M, Pienta KJ, Pomper MG, DeWeese TL, Dicker A, Eisenberger M, Tran PT.

BMC Cancer. 2017 Jun 29;17(1):453. doi: 10.1186/s12885-017-3455-6.

11.

A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial).

Mercier C, Dirix P, Meijnders P, Vermeulen P, Van Laere S, Debois H, Huget P, Verellen D.

Radiat Oncol. 2018 Aug 20;13(1):152. doi: 10.1186/s13014-018-1096-9.

12.

Treatment of metastatic liver tumors using stereotactic ablative radiotherapy.

Nair VJ, Pantarotto JR.

World J Radiol. 2014 Feb 28;6(2):18-25. doi: 10.4329/wjr.v6.i2.18. Review.

13.

Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial.

Palma DA, Haasbeek CJ, Rodrigues GB, Dahele M, Lock M, Yaremko B, Olson R, Liu M, Panarotto J, Griffioen GH, Gaede S, Slotman B, Senan S.

BMC Cancer. 2012 Jul 23;12:305. doi: 10.1186/1471-2407-12-305.

14.

A Review of Ongoing Trials of Stereotactic Ablative Radiotherapy for Oligometastatic Cancers: Where Will the Evidence Lead?

Al-Shafa F, Arifin AJ, Rodrigues GB, Palma DA, Louie AV.

Front Oncol. 2019 Jun 21;9:543. doi: 10.3389/fonc.2019.00543. eCollection 2019. Review.

15.

The emerging roles of stereotactic ablative radiotherapy for metastatic renal cell carcinoma.

Cheung P, Thibault I, Bjarnason GA.

Curr Opin Support Palliat Care. 2014 Sep;8(3):258-64. doi: 10.1097/SPC.0000000000000074. Review.

PMID:
25090288
16.

Stereotactic ablative body radiotherapy for lung cancer.

Franks KN, Jain P, Snee MP.

Clin Oncol (R Coll Radiol). 2015 May;27(5):280-9. doi: 10.1016/j.clon.2015.01.006. Epub 2015 Mar 4.

PMID:
25746732
17.

CyberKnife Stereotactic Ablative Radiotherapy as an Option of Treatment for Patients With Prostate Cancer Having Oligometastatic Lymph Nodes: Single-Center Study Outcome Evaluation.

Napieralska A, Miszczyk L, Stąpór-Fudzińska M.

Technol Cancer Res Treat. 2016 Oct;15(5):661-73. doi: 10.1177/1533034615595945. Epub 2015 Jul 24.

PMID:
26208835
18.

Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.

Parikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, Pitcher S, Lee SP, Inouye WS, Jordan ML, Sanati H, Jafari L, Bennett CJ, Gin GE, Kishan AU, Reiter RE, Lewis M, Sadeghi A, Aronson WJ, Garraway IP, Rettig MB, Nickols NG.

BMC Cancer. 2019 Apr 1;19(1):291. doi: 10.1186/s12885-019-5496-5.

19.

CyberKnife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases.

Napieralska A, Miszczyk L, Stapor-Fudzinska M.

Neoplasma. 2016;63(2):304-12. doi: 10.4149/218_150807N435.

PMID:
26774153
20.

New concepts and insights into the role of radiation therapy in extracranial metastatic disease.

Ricardi U, Filippi AR, Franco P.

Expert Rev Anticancer Ther. 2013 Oct;13(10):1145-55. doi: 10.1586/14737140.2013.846829. Review.

PMID:
24134418

Supplemental Content

Support Center